Posted On: 01/04/2016 9:14:32 AM
Post# of 144158
![Avatar](https://investorshangout.com/images/ProfileImages/1720927361_3360_francarob.jpg)
ITNS .0022 News Itonis, Inc. narrows its selection for its anti-nausea product Emesyl to two manufacturers
Source: InvestorsHub NewsWire
Itonis, Inc. narrows its selection for its anti-nausea product Emesyl to two manufacturers
LAGUNA HILLS, CA -- December 30, 2015 -- InvestorsHub NewsWire -- Itonis, Inc. (OTC PINKSHEETS: ITNS) Itonis, Inc. is pleased to announce that it has narrowed its selection to two homeopathic manufacturers for the production of its anti-nausea product Emesyl.
The company has been searching for a new homeopathic manufacturer for Emesyl since Oasis Health Products went out of business and failed to deliver 15,000 units from its initial fully paid product order. Selection of the new manufacturer will be announced early 2016 and newly manufactured Emesyl product is expected to be back in the pipeline for sale immediately after completion of stability testing on the first new lot.
The company will also move forward with the release of the 10,000 commercial spots it previously announced to be aired on cable TV, once new product is manufactured and back in the pipeline. The company was forced to put this project on hold when product availability came to a halt as the result of Oasis Health Products going out of business.
Additionally, the company has been working with its software developer to upgrade the Emesyl.com website to a new platform, which will include an online shopping cart. This will allow for direct consumer purchase of Emesyl from the website.
The Oasis issue was a huge setback for us said Steve Pidliskey, Itonis Vice President. We knew up front that the selection of a new homeopathic manufacturer with proper FDA registered facilities would be a time consuming process. Fortunately, were back on our feet now, and were confident that our goal of making Emesyl a household name will be achieved.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyEChecks patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact:
Itonis, Inc.
Office@itonisholdings.com
Source: InvestorsHub NewsWire
Itonis, Inc. narrows its selection for its anti-nausea product Emesyl to two manufacturers
LAGUNA HILLS, CA -- December 30, 2015 -- InvestorsHub NewsWire -- Itonis, Inc. (OTC PINKSHEETS: ITNS) Itonis, Inc. is pleased to announce that it has narrowed its selection to two homeopathic manufacturers for the production of its anti-nausea product Emesyl.
The company has been searching for a new homeopathic manufacturer for Emesyl since Oasis Health Products went out of business and failed to deliver 15,000 units from its initial fully paid product order. Selection of the new manufacturer will be announced early 2016 and newly manufactured Emesyl product is expected to be back in the pipeline for sale immediately after completion of stability testing on the first new lot.
The company will also move forward with the release of the 10,000 commercial spots it previously announced to be aired on cable TV, once new product is manufactured and back in the pipeline. The company was forced to put this project on hold when product availability came to a halt as the result of Oasis Health Products going out of business.
Additionally, the company has been working with its software developer to upgrade the Emesyl.com website to a new platform, which will include an online shopping cart. This will allow for direct consumer purchase of Emesyl from the website.
The Oasis issue was a huge setback for us said Steve Pidliskey, Itonis Vice President. We knew up front that the selection of a new homeopathic manufacturer with proper FDA registered facilities would be a time consuming process. Fortunately, were back on our feet now, and were confident that our goal of making Emesyl a household name will be achieved.
About Itonis, Inc.
Located in Laguna Hills, California, and founded in 2005, Itonis Inc. has focused on the distribution of innovative products to the medical and pharmaceutical industries. The company also holds a licensing agreement with MyECheck Inc, which allows the company to use MyEChecks patented mobile payment application and share transaction revenue fees for point of purchase payments across various industries. Please visit www.itonisholdings.com for additional information.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
Contact:
Itonis, Inc.
Office@itonisholdings.com
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)